In a report released today, Serge Belanger from Needham maintained a Buy rating on Heron Therapeutics (HRTX), with a price target of $28.00. The company’s shares closed last Thursday at $15.54.
According to TipRanks.com, Belanger is a 4-star analyst with an average return of 5.8% and a 47.4% success rate. Belanger covers the Healthcare sector, focusing on stocks such as Amphastar Pharmaceuticals, KalVista Pharmaceuticals, and Collegium Pharmaceutical.
Heron Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $29.00, a 61.6% upside from current levels. In a report issued on April 29, Northland Securities also assigned a Buy rating to the stock with a $35.00 price target.
See today’s analyst top recommended stocks >>
Based on Heron Therapeutics’ latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $20.02 million and GAAP net loss of $52.61 million. In comparison, last year the company earned revenue of $25.4 million and had a GAAP net loss of $51.58 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Heron Therapeutics, Inc. is a biotechnology company, which develops pharmaceutical products for patients suffering from cancer. The company develops products by using its proprietary Biochronomer polymer based drug delivery technology. Its products include SUSTOL, Pipeline, Cinvanti and HTX-011. The company has additional clinical and preclinical-stage programs in the area of pain management, all of which utilize its bio erodible, injectable and implantable delivery systems. Heron Therapeutics was founded in February 1983 and is headquartered in Redwood City, CA.
